Skip to main content
. 2023 Jun 10;299(7):104909. doi: 10.1016/j.jbc.2023.104909

Figure 7.

Figure 7

Knockdown of SHMT2/MTHFD2 promotes liver fibrosis resolution in NASH mice.A, schematic illustrating animal experimental design. B and C, liver Shmt2 and Mthfd2 mRNA levels. Ad-shRNA–medicated Shmt2 and Mthfd2 knockdown in mouse liver tissue (n = 4). D, schematic representation of vitamin A–coupled liposomes nanoparticle for the delivery of siRNA. E, representative image of H&E, Masson, and sirius red–stained paraffin-embedded sections of mouse liver tissues (scale bar represents 50 μm). F, Ishak fibrosis stage scores at indicated treatment conditions (n = 6). G, hepatic hydroxyproline content (n = 6). H and I, ALT and AST levels of plasma (n = 6). J and K, hepatic mRNA expression of fibrogenic genes Acta2 and Col1a1 (n = 5). The statistical significance (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001) was tested by student’s unpaired t test. AST, aspartate aminotransferase; ALT, alanine aminotransferase; H&E, hematoxylin-eosin staining; MTHFD, methylenetetrahydrofolate dehydrogenase; NASH, nonalcoholic steatohepatitis; SHMT, serine hydroxymethyltransferase.